Martin David Harp

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1).

The trial is evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP).

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Broadwood and Yunqi Capital will add 3 total members to the board, while the CEO and more step down.

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

The trial is being discontinued based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for “futility."

While primary endpoint analysis showed no statistical difference in the rate of change in GA area between AVD-104 versus monthly avacincaptad pegol, 12-month results showed approximately 31% reduction in GA lesion growth rate versus growth rates in sham and natural history rates.

The company plans to submit its NDA package in the second half of 2026.

Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the merger process.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

EndoArt is an artificial cornea endothelial layer made of a sterile biocompatible material, acrylic hydrophilic. According to the company it is the first synthetic implant to treat corneal edema.